VP1-2022: Pre-specified event driven analysis of Overall Survival (OS) in the OlympiA phase III trial of adjuvant olaparib (OL) in germline BRCA1/2 mutation (gBRCAm) associated breast cancer

Saved in:
Bibliographic Details
Published inAnnals of oncology Vol. 33; no. 5; pp. 566 - 568
Main Authors Tutt, A.N.J., Garber, J., Gelber, R.D., Phillips, K-A., Eisen, A., Johannsson, O.T., Rastogi, P., Cui, K.Y., Im, S-A., Yerushalmi, R., Brufsky, A.M., Taboada, M., Rossi, G., Yothers, G., Singer, C., Fein, L.E., Loman, N., Cameron, D., Campbell, C., Geyer, C.E.
Format Journal Article
LanguageEnglish
Published Elsevier Ltd 01.05.2022
Online AccessGet full text

Cover

More Information
ISSN:0923-7534
1569-8041
DOI:10.1016/j.annonc.2022.03.008